Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 1,777 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Esophagus Disorder Clear all
Recruiting Phase 1 Interventional

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma

NCT06623396
View directory record Official record
Conditions
Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
Interventions
M28z1XXPD1DNR CAR
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

NCT03561090
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
IW-3718, placebo, Standard-dose PPIs QD
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
93
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 29, 2026, 4:02 AM EDT
Terminated Not applicable Interventional

Hiatal Interrogation in Sleeve Gastrectomy

NCT03527810
View directory record Official record
Conditions
Sleeve Gastrectomy
Interventions
Sleeve Gastrectomy Without Interrogation of Hiatus, Sleeve Gastrectomy With Interrogation of Hiatus
Procedure
Lead sponsor
Miguel Burch
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2022 · Synced Oct 29, 2026, 4:02 AM EDT
Recruiting Phase 1 Interventional

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

NCT00321737
View directory record Official record
Conditions
Esophagitis, Reflux, Esophagitis, Peptic
Interventions
Dexlansoprazole MR, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
80
States / cities
Huntsville, Alabama • Tuscon, Arizona • Anaheim, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 2Phase 3 Interventional

Pharyngocise Dose Response Study

NCT01279837
View directory record Official record
Conditions
Dysphagia
Interventions
Pharyngocise
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 90 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 29, 2026, 4:02 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)

NCT02634645
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Cancer
Interventions
Endoscopic eradication therapies (EET), Esophagectomy, Chemotherapy, Radiation
Procedure · Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 29, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

NCT04949256
View directory record Official record
Conditions
Metastatic Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Paclitaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
863 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Duarte, California • Washington D.C., District of Columbia • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional

Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)

NCT06783751
View directory record Official record
Conditions
Obesity, Bariatric Surgery, Sleeve Gastrectomy, Gastroesophageal Reflux Disease
Interventions
Modified Vertical Sleeve Gastrectomy (mVSG), Conventional Vertical Sleeve Gastrectomy (cVSG)
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Orange, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Not applicable Interventional Results available

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

NCT04526886
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer, Small Bowel Cancer, Appendix Cancer
Interventions
Algorithm for cytopenia-related delay and dose-reduction of mFOLFOX chemotherapy
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 29, 2026, 4:02 AM EDT
Recruiting No phase listed Observational

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642
View directory record Official record
Conditions
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Liver Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Skin Neoplasm, Metastatic Malignant Solid Neoplasm, Resectable Lung Non-Small Cell Carcinoma, Early Stage Lung Non-Small Cell Carcinoma, Resectable Malignant Solid Neoplasm, Resectable Triple-Negative Breast Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Cervical Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Recurrent Cervical Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Malignant Skin Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Tissue Collection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach

NCT00020761
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
irinotecan hydrochloride, paclitaxel
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).

NCT00171483
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Tegaserod
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Timeline
2004 – 2005
U.S. locations
7
States / cities
Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 4 Interventional

Esophageal and Laryngeal Tissue Changes in Patients Suspected of Having Laryngopharyngeal Reflux

NCT00373997
View directory record Official record
Conditions
Larynx Disease, Gastroesophageal Reflux
Interventions
Esophageal and Laryngeal biopsies, egd with biopsy
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 29, 2026, 4:02 AM EDT
Completed No phase listed Observational

ConMed Beamer Study

NCT04752670
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Achalasia, Gastroparesis
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 29, 2026, 4:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Natural History of Gastroesophageal Reflux (GER) in Children and Adolescents

NCT00181805
View directory record Official record
Conditions
Gastroesophageal Reflux
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis

NCT01048866
View directory record Official record
Conditions
Pharyngitis
Interventions
placebo, flurbiprofen, acetaminophen 650mg
Drug
Lead sponsor
Reckitt Benckiser LLC
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 29, 2026, 4:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Movement of Epiglottis During Swallowing

NCT00475943
View directory record Official record
Conditions
Deglutition, Dysphagia
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 4:02 AM EDT
Not listed No phase listed Observational

Management of Esophagitis Following Repair of Esophageal Atresia

NCT03619408
View directory record Official record
Conditions
Esophageal Atresia, Esophagitis
Interventions
Antacids
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 17 Years
Enrollment
50 participants
Timeline
2019 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2021 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Topical Bethanechol for Improvement of Esophageal Dysmotility

NCT01031043
View directory record Official record
Conditions
Esophageal Dysmotility
Interventions
Bethanechol
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2015 · Synced Oct 29, 2026, 4:02 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Study to Evaluate EnteroTracker® as a Sampling Method to Screen for Barrett's Esophagus/Esophageal Cancer

NCT05706025
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
EnteroTracker
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 29, 2026, 4:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

NCT03228407
View directory record Official record
Conditions
Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
Interventions
Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
Procedure · Diagnostic Test
Lead sponsor
McGuire Research Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers

NCT02642809
View directory record Official record
Conditions
Esophageal Cancer, Cancer of the Esophagus
Interventions
Pembrolizumab, Brachytherapy
Drug · Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 29, 2026, 4:02 AM EDT
Completed Not applicable Interventional

Impact of Swaddle Blanket on Gastroesophageal Reflux

NCT02083952
View directory record Official record
Conditions
Gastroesophageal Reflux, Apnea, Bradycardia, Oxygen Desaturations
Interventions
Swaddle Blanket
Other
Lead sponsor
Valley Health System
Other
Eligibility
2 Days to 180 Days
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Ridgewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 29, 2026, 4:02 AM EDT